A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Hepatorenal syndrome (HRS) is a life-threatening condition marked by rapid decline in kidney
function in patients with liver cirrhosis or fulminant liver failure. Vasodilation in the
gastrointestinal region is largely thought to contribute to the disease. LJPC-501 is a
vasoconstrictor that may restore proper circulation and kidney function in patients with HRS.